KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to 0.92.

  • Xenon Pharmaceuticals' Equity Ratio fell 355.51% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year decrease of 355.51%. This contributed to the annual value of 0.95 for FY2024, which is 165.82% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Equity Ratio stood at 0.92 for Q3 2025, which was down 355.51% from 0.94 recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Equity Ratio ranged from a high of 0.97 in Q2 2022 and a low of 0.92 during Q3 2025
  • In the last 5 years, Xenon Pharmaceuticals' Equity Ratio had a median value of 0.95 in 2023 and averaged 0.95.
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 1985.69% in 2021, then tumbled by 355.51% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Equity Ratio (Quarter) stood at 0.96 in 2021, then decreased by 0.51% to 0.96 in 2022, then rose by 0.53% to 0.96 in 2023, then fell by 1.66% to 0.95 in 2024, then fell by 2.68% to 0.92 in 2025.
  • Its Equity Ratio stands at 0.92 for Q3 2025, versus 0.94 for Q2 2025 and 0.95 for Q1 2025.